MiR-199b-5p targets HER2 in breast cancer cells

Journal of Cellular Biochemistry

Volumn 114, Issue 7, 2013, Pages 1457-1463

  Fang, Chen ^a   Zhao, Yu ^b   Guo, Baoyu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

BREAST CANCER; HER2; microRNA; miR 199b 5p

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 199B 5P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL SURVIVAL; CLONOGENESIS; COLONY FORMING CELL; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA ISOLATION; TRANSIENT TRANSFECTION; WESTERN BLOTTING; WOUND HEALING;

3' UNTRANSLATED REGIONS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICRORNAS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WOUND HEALING;

EID: 84877688272     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24487     Document Type: Article

References (32)

1. Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T,. 2011. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 411: 804-808.
2. Ambros V,. 2001. microRNAs: Tiny regulators with great potential. Cell 107: 823-826. (Pubitemid 34084973)
3. Bartel DP,. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
4. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA,. 2007. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
5. Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, Wang CJ, Tsai CN, Lee YS, Wang TH, Lai CH,. 2010. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett 291: 99-107.
6. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM,. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949. (Pubitemid 41377683)
7. Croce CM,. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
8. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J,. 2008. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221-9230.
9. Esquela-Kerscher A, Slack FJ,. 2006. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
10. Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, Rasko JE,. 2010. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95: 1325-1333.
11. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M,. 2009. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 4: e4998.
12. Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K,. 2012. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS ONE 7: e31422.
13. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ,. 2005. RAS is regulated by the let-7 microRNA family. Cell 120: 635-647. (Pubitemid 40343076)
14. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ,. 1991. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49: 650-655.
15. Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC, Jr., 2012. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS ONE 7: e41170.
16. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB,. 2003. Prediction of mammalian microRNA targets. Cell 115: 787-798. (Pubitemid 38058492)
17. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM,. 2009. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 69: 6871-6878.
18. Lynam-Lennon N, Maher SG, Reynolds JV,. 2009. The roles of microRNA in cancer and apoptosis. Biol Rev 84: 55-71.
19. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P,. 2008. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 74: 807-822.
20. Molina MA, Sáez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, García-Conde J,. 2002. NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347-353. (Pubitemid 34193949)
21. Mukohara T,. 2011. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 102: 1-8.
22. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, Loman N, Jonsson G, Naya H, Hoglund M, Borg A, Rovira C,. 2011. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 71: 78-86.
23. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R, Justice R, Pazdur R,. 2008. FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13: 1114-1119.
24. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, y Cajal SR, Arribas J,. 2007. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638. (Pubitemid 47073544)
25. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC,. 2007. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282: 1479-1486. (Pubitemid 47076526)
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
27. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ,. 2007. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369: 29-36. (Pubitemid 46039831)
28. Stahlhut Espinosa CE, Slack FJ,. 2006. The role of microRNAs in cancer. Yale J Biol Med 79: 131-140.
29. Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, Yamada Y, Toyoshima K, Yamamoto T,. 1990. Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659-Glu659). EMBO J 9: 181-190.
30. Trowe T, Boukouvala S, Calkins K, Cutler RE, Jr., Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS,. 2008. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14: 2465-2475. (Pubitemid 351551082)
31. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, Moseley MA III, Thompson JW, Chen FL, Koch KM, Spector NL,. 2010. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 9: 292-299.
32. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY,. 2008. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359. (Pubitemid 351333899)